Suchergebnisse - "NUC-1031"

PubPharm (14)

1

Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells In Vitro

enthalten in: Journal of medicinal chemistry | 2021

von Slusarczyk, M. | Serpi, M. | Ghazaly, E. | +3

2

A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Kazmi, F. | Nicum, S. | Roux, R. | +8

3

In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)"

enthalten in: The oncologist | 2021

von Ricci, A. | Rizzo, A. | Brandi, G.

CommentOn: Oncologist. 2021 Apr;26(4):e669-e678. - PMID 33210382

4

A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)

enthalten in: The oncologist | 2021

von McNamara, M. | Bridgewater, J. | Palmer, D. | +9

CommentIn: Oncologist. 2021 May;26(5):e902. - PMID 33539601

5

Evaluation of NUC-1031 : a first-in-class ProTide in biliary tract cancer

enthalten in: Cancer chemotherapy and pharmacology | 2020

von Arora, M. | Bogenberger, J. | Abdelrahman, A. | +15

6

NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)

enthalten in: Future oncology (London, England) | 2020

von McNamara, M. | Goyal, L. | Doherty, M. | +12

7

NUC-1031, use of ProTide technology to circumvent gemcitabine resistance : current status in clinical trials

enthalten in: Medical oncology (Northwood, London, England) | 2020

von Kapacee, Z. | Knox, J. | Palmer, D. | +4

8

NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials

enthalten in: Medical oncology | 2020

von Kapacee, Z. | Knox, J. | Palmer, D. | +4

9

NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials

enthalten in: Medical oncology | 2020

von Kapacee, Z. | Knox, J. | Palmer, D. | +4

10

NUC-1031 in biliary tract cancer : from bench to bedside and back?

enthalten in: Cancer chemotherapy and pharmacology | 2020

von Boyd, L. | Peters, G. | Kazemier, G. | +1